QNTM
Quantum BioPharma Ltd.
Drug Manufacturers - Specialty & Generic
Market Cap$21M
5Y Perf.-97.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
QNTM vs CMPS
Revenue, margins, valuation, and 5-year total return — side by side.
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.-71.6%
QNTM vs CMPS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | QNTM | CMPS |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Care Facilities |
| Market Cap | $21M | $902M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-26M | $-288M |
| Total Debt | $2M | $21M |
| Cash & Equiv. | $2M | $150M |
QNTM vs CMPS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
QNTM
CMPS
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Quantum BioPharma L… (QNTM) | 100 | 2.9 | -97.1% |
| COMPASS Pathways plc (CMPS) | 100 | 28.4 | -71.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: QNTM vs CMPS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CMPS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Quantum BioPharma Ltd. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
QNTM
Quantum BioPharma Ltd.
The Income Pick
QNTM is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.98
- EPS growth 35.1%
- Lower volatility, beta 0.98, Low D/E 36.8%, current ratio 1.07x
Best for: income & stability and growth exposure
CMPS
COMPASS Pathways plc
The Long-Run Compounder
CMPS carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -67.6% 10Y total return vs QNTM's -99.6%
- -85.7% revenue growth vs QNTM's -87.2%
- 1.3% margin vs QNTM's -3.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CMPS | -85.7% revenue growth vs QNTM's -87.2% |
| Quality / Margins | CMPS | 1.3% margin vs QNTM's -3.5% |
| Stability / Safety | QNTM | Beta 0.98 vs CMPS's 1.33 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CMPS | +151.1% vs QNTM's -40.4% |
| Efficiency (ROA) | CMPS | -106.8% ROA vs QNTM's -189.1% |
QNTM vs CMPS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCMPSLAGGINGQNTM
QNTMQuantum BioPharma Ltd.
1leads
CMPSCOMPASS Pathways plc
3leads
6 Total Categories
CATEGORYLEADERvs QNTMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
QNTM1/1
Valuation MetricsMultiples, price ratios, and targets
CMPS1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CMPS4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CMPS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
QNTM leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
QNTM and CMPS operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | QNTMQuantum BioPharma… | CMPSCOMPASS Pathways … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$15M | -$179M |
| Net IncomeAfter-tax profit | -$26M | -$288M |
| Free Cash FlowCash after capex | -$8M | -$157M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +84.9% | -58.7% |
QNTM leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CMPS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | QNTMQuantum BioPharma… | CMPSCOMPASS Pathways … |
|---|---|---|
| Market CapShares × price | $21M | $902M |
| Enterprise ValueMkt cap + debt − cash | $21M | $774M |
| Trailing P/EPrice ÷ TTM EPS | -0.62x | -3.05x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 3.23x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
CMPS leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
CMPS leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
CMPS delivers a -3.4% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-5 for QNTM. On the Piotroski fundamental quality scale (0–9), CMPS scores 2/9 vs QNTM's 1/9, reflecting mixed financial health.
| Metric | QNTMQuantum BioPharma… | CMPSCOMPASS Pathways … |
|---|---|---|
| ROE (TTM)Return on equity | -5.5% | -3.4% |
| ROA (TTM)Return on assets | -189.1% | -106.8% |
| ROICReturn on invested capital | -2.3% | — |
| ROCEReturn on capital employed | -2.0% | -2.5% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.37x | — |
| Net DebtTotal debt minus cash | -$29,093 | -$129M |
| Cash & Equiv.Liquid assets | $2M | $150M |
| Total DebtShort + long-term debt | $2M | $21M |
| Interest CoverageEBIT ÷ Interest expense | -32.67x | -52.40x |
CMPS leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CMPS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CMPS five years ago would be worth $2,756 today (with dividends reinvested), compared to $453 for QNTM. Over the past 12 months, CMPS leads with a +151.1% total return vs QNTM's -40.4%. The 3-year compound annual growth rate (CAGR) favors CMPS at 3.5% vs QNTM's -60.2% — a key indicator of consistent wealth creation.
| Metric | QNTMQuantum BioPharma… | CMPSCOMPASS Pathways … |
|---|---|---|
| YTD ReturnYear-to-date | -28.5% | +43.4% |
| 1-Year ReturnPast 12 months | -40.4% | +151.1% |
| 3-Year ReturnCumulative with dividends | -93.7% | +11.0% |
| 5-Year ReturnCumulative with dividends | -95.5% | -72.4% |
| 10-Year ReturnCumulative with dividends | -99.6% | -67.6% |
| CAGR (3Y)Annualised 3-year return | -60.2% | +3.5% |
CMPS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — QNTM and CMPS each lead in 1 of 2 comparable metrics.
Risk & Volatility
QNTM is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than CMPS's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CMPS currently trades 92.0% from its 52-week high vs QNTM's 13.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | QNTMQuantum BioPharma… | CMPSCOMPASS Pathways … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.97x | 1.28x |
| 52-Week HighHighest price in past year | $38.25 | $10.21 |
| 52-Week LowLowest price in past year | $2.07 | $2.25 |
| % of 52W HighCurrent price vs 52-week peak | +13.1% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 62.5 | 68.1 |
| Avg Volume (50D)Average daily shares traded | 495K | 3.7M |
Evenly matched — QNTM and CMPS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | QNTMQuantum BioPharma… | CMPSCOMPASS Pathways … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $18.00 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CMPS leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). QNTM leads in 1 (Income & Cash Flow). 1 tied.
Best OverallCOMPASS Pathways plc (CMPS)Leads 3 of 6 categories
Loading custom metrics...
QNTM vs CMPS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is QNTM or CMPS a better buy right now?
Analysts rate COMPASS Pathways plc (CMPS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — QNTM or CMPS?
Over the past 5 years, COMPASS Pathways plc (CMPS) delivered a total return of -72.
4%, compared to -95. 5% for Quantum BioPharma Ltd. (QNTM). Over 10 years, the gap is even starker: CMPS returned -65. 8% versus QNTM's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — QNTM or CMPS?
By beta (market sensitivity over 5 years), Quantum BioPharma Ltd.
(QNTM) is the lower-risk stock at 0. 97β versus COMPASS Pathways plc's 1. 28β — meaning CMPS is approximately 32% more volatile than QNTM relative to the S&P 500.
04Which is growing faster — QNTM or CMPS?
On earnings-per-share growth, the picture is similar: Quantum BioPharma Ltd.
grew EPS 35. 1% year-over-year, compared to -33. 9% for COMPASS Pathways plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — QNTM or CMPS?
Quantum BioPharma Ltd.
(QNTM) is the more profitable company, earning 0. 0% net margin versus 0. 0% for COMPASS Pathways plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QNTM leads at 0. 0% versus 0. 0% for CMPS. At the gross margin level — before operating expenses — QNTM leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — QNTM or CMPS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is QNTM or CMPS better for a retirement portfolio?
For long-horizon retirement investors, Quantum BioPharma Ltd.
(QNTM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97)). Both have compounded well over 10 years (QNTM: -99. 6%, CMPS: -65. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between QNTM and CMPS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.